Target intelligence / Profile preview

Mechanical support and local sirolimus delivery (medical device function)

Molecular classification
Other (medical device/drug-device combination), Not a molecular target
01

Overview

The name provided does not refer to a specific molecule or receptor but to the function of bioresorbable vascular scaffolds or sirolimus-eluting stents/balloons. These drug-device combination products are implanted into blood vessels, usually coronary arteries, to mechanically support the vessel wall after angioplasty, preventing immediate vessel recoil and negative remodeling, while locally eluting sirolimus over weeks to months. Sirolimus inhibits neointimal hyperplasia by blocking vascular smooth muscle cell proliferation and migration, thus reducing the risk of restenosis. These devices represent an important advance over bare-metal stents by addressing both the mechanical and biological causes of vessel narrowing after intervention. Their use is associated with limited systemic sirolimus exposure and specific procedural and vascular safety considerations. This entry is not a canonical therapeutic target but describes a device-mediated therapeutic strategy for vascular interventions.

Other names
Mechanical vascular scaffold (device)Sirolimus-eluting stent (SES)Sirolimus-eluting bioresorbable vascular scaffold (BRS)Drug-eluting balloon (DEB), sirolimus-coatedDrug-eluting stent (DES), sirolimus type
02

Mechanism of action

Local elution of sirolimus to inhibit proliferation and migration of vascular smooth muscle cells, blocking cell cycle progression. Mechanical scaffolding to prevent vessel recoil and negative remodeling.

03

Biological functions

Mechanical support of blood vessel (prevention of elastic recoil)Local drug delivery (sirolimus, antiproliferative)
04

Disease associations

Cardiovascular diseasePrevention of restenosisCoronary artery disease
05

Safety considerations

Stent thrombosisDelayed healing and late restenosisLate malappositionLocal vascular toxicity (rare)Systemic exposure to sirolimus (minimized by device design)Target lesion failure
06

Interacting drugs

Sirolimus (primary antiproliferative agent)

1 more in the full profile.

07

Biomarkers

Not associated with molecular biomarkers; endpoints are angiographic (e.g., minimal lumen diameter, in-stent restenosis)Proliferating cell nuclear antigen, retinoblastoma protein (in research settings)

Beyond the preview

Go deeper on Mechanical support and local sirolimus delivery (medical device function).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mechanical support and local sirolimus delivery (medical device function).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call